Chugai Reports NDA Submission of Risdiplam to the MHLW as the First Oral Drug for SMA in Japan

  • by

Shots:

  • The NDA submission is based on FIREFISH study assessing Risdiplam in infants with symptomatic SMA Type 1 & SUNFISH study in children and young adults with SMA Type 2 or 3
  • FIRESISH study results: improvement in survival and motor milestones in infants. SUNFISH study results: improvement in motor function in people aged 2-25 with type 2 or 3 SMA
  • Risdiplam (PO) is a therapy designed to increase and sustain SMN protein levels in the CNS & throughout the body. The therapy has received MHLW’s ODD on Mar 27, 2020, and is a subject to PR in Japan

Click here ­to­ read full press release/ article | Ref: Chugai | Image: Financial Times

The post Chugai Reports NDA Submission of Risdiplam to the MHLW as the First Oral Drug for SMA in Japan first appeared on PharmaShots.